These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain. Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680 [TBL] [Abstract][Full Text] [Related]
12. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP). Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207 [TBL] [Abstract][Full Text] [Related]
13. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age. Cieslak CM Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539 [TBL] [Abstract][Full Text] [Related]
14. Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants. Domachowske JB; Khan AA; Esser MT; Jensen K; Takas T; Villafana T; Dubovsky F; Griffin MP Pediatr Infect Dis J; 2018 Sep; 37(9):886-892. PubMed ID: 29373476 [TBL] [Abstract][Full Text] [Related]
15. Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model. Kieffer A; Beuvelet M; Sardesai A; Musci R; Milev S; Roiz J; Lee JKH J Infect Dis; 2022 Aug; 226(Suppl 2):S282-S292. PubMed ID: 35968866 [TBL] [Abstract][Full Text] [Related]
16. Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants. Wilkins D; Yuan Y; Chang Y; Aksyuk AA; Núñez BS; Wählby-Hamrén U; Zhang T; Abram ME; Leach A; Villafana T; Esser MT Nat Med; 2023 May; 29(5):1172-1179. PubMed ID: 37095249 [TBL] [Abstract][Full Text] [Related]
17. Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. Domachowske J; Madhi SA; Simões EAF; Atanasova V; Cabañas F; Furuno K; Garcia-Garcia ML; Grantina I; Nguyen KA; Brooks D; Chang Y; Leach A; Takas T; Yuan Y; Griffin MP; Mankad VS; Villafana T; N Engl J Med; 2022 Mar; 386(9):892-894. PubMed ID: 35235733 [No Abstract] [Full Text] [Related]
18. Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024. Moline HL; Tannis A; Toepfer AP; Williams JV; Boom JA; Englund JA; Halasa NB; Staat MA; Weinberg GA; Selvarangan R; Michaels MG; Sahni LC; Klein EJ; Stewart LS; Schlaudecker EP; Szilagyi PG; Schuster JE; Goldstein L; Musa S; Piedra PA; Zerr DM; Betters KA; Rohlfs C; Albertin C; Banerjee D; McKeever ER; Kalman C; Clopper BR; ; McMorrow ML; Dawood FS MMWR Morb Mortal Wkly Rep; 2024 Mar; 73(9):209-214. PubMed ID: 38457312 [TBL] [Abstract][Full Text] [Related]
19. Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants. Drysdale SB; Cathie K; Flamein F; Knuf M; Collins AM; Hill HC; Kaiser F; Cohen R; Pinquier D; Felter CT; Vassilouthis NC; Jin J; Bangert M; Mari K; Nteene R; Wague S; Roberts M; Tissières P; Royal S; Faust SN; N Engl J Med; 2023 Dec; 389(26):2425-2435. PubMed ID: 38157500 [TBL] [Abstract][Full Text] [Related]
20. Exploratory analysis of the economically justifiable price of nirsevimab for healthy late-preterm and term infants in Colombia. Buendía JA; Acuña-Cordero R; Rodriguez-Martinez CE Pediatr Pulmonol; 2024 May; 59(5):1372-1379. PubMed ID: 38358037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]